Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.51 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12676173 | 1.00 | ACHE (0.66) | ACHECYP19A1CES1NPC1RAB9A | |
| SCHEMBL25001243 | 1.00 | ACHE (0.66) | ACHECYP19A1CES1NPC1RAB9A | |
| SCHEMBL677613 | 1.00 | ACHE (0.66) | ACHECYP19A1CES1NPC1RAB9A | |
| SCHEMBL677669 | 0.89 | ACHE (0.61) | ACHECYP19A1CES1NPC1RAB9A | |
| SCHEMBL354925 | 0.79 | ACHE (1.00) | ACHECYP19A1TSHR | |
| SCHEMBL4938272 | 0.79 | ACHE (1.00) | ACHECYP19A1TSHR | |
| SCHEMBL9752693 | 0.79 | ACHE (1.00) | ACHECYP19A1TSHR | |
| SCHEMBL13866434 | 0.79 | ACHE (1.00) | ACHECYP19A1TSHR | |
| SCHEMBL13039620 | 0.79 | DRD2 (0.56) | ACHECYP19A1CES1DRD2HTR2A | |
| SCHEMBL28793725 | 0.78 | ACHE (0.44) | ACHEALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113185433-B | Preparation method of menadione sodium bisulfate | 新发药业有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-113185433-B | Preparation method of menadione sodium bisulfate | 新发药业有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-115974850-A | Compound serving as AKR1C3 inhibitor and preparation method and application thereof | 中国药科大学 | 2023-04-18 | — | — | CN | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| CN-113185433-A | Preparation method of menadione sodium bisulfite | 新发药业有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113185433-A | Preparation method of menadione sodium bisulfite | 新发药业有限公司 | 2021-07-30 | — | — | CN | disclosed |
| EP-3649184-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-3492465-A1 | S1P1 AGONIST AND APPLICATION THEREOF | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| WO-2019010265-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | disclosed |
| EP-3380587-A2 | PROCESS OF UPGRADING LIGHT HYDROCARBONS AND OXYGENATES PRODUCED DURING CATALYTIC PYROLYSIS OF BIOMASS | Inaeris Technologies, LLC (US) | 2018-10-03 | — | — | EP | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | EISAI CO., LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| WO-2004034963-A2 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | WO | disclosed |
| EP-0311086-A1 | N-fluorinated sulfon amides, process for their preparation and their use | CIBA-GEIGY AG (CH) | 1989-04-12 | — | — | EP | disclosed |
| EP-0103990-A1 | Process for making diarylamines | UNIROYAL, INC. (US) | 1984-03-28 | — | — | EP | disclosed |
| US-4431841-A | REACTING PRIMARY AROMATIC AMINES AND ALICYCLIC KETONES USING AN ACID PROMOTER AND A PLATINUM CATALYST | UNIROYAL, INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4355180-A | Preparation of primary aromatic amines from cyclic alcohols and/or ketones | BASF AKTIENGESELLSCHAFT (DE) | 1982-10-19 | — | — | US | disclosed |
| EP-0050229-A1 | Process for the preparation of primary aromatic amines from cyclic alcohols and/or ketones | BASF Aktiengesellschaft (DE) | 1982-04-28 | — | — | EP | disclosed |
| US-4016281-A | Tetralone and indanone compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | ACHE 1/4885CYP19A1 1004/4885CES1 109/4885 |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | ACHE, BPHL, GLA | ACHE 1/4885CYP19A1 3032/4885CES1 2026/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | ACHE 4/4885CYP19A1 2172/4885CES1 1013/4885 |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | ACHE, CHAT, BCHE | ACHE 1/4885CYP19A1 3635/4885CES1 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.